SJS Investment Consulting’s Catalyst Pharmaceutical CPRX Stock Holding History

SJS Investment Consulting’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$189	Buy	6 +4	+200%	+$118	﹤0.01%	2487
2026 Q1	$50	Hold	2	–	–	﹤0.01%	2252
2025 Q4	$47	Hold	2	–	–	﹤0.01%	2025
2025 Q3	$40	Hold	2	–	–	﹤0.01%	1619
2025 Q2	$44	Sell	2 -1	-33%	-$24	﹤0.01%	1522
2025 Q1	$73	Hold	3	–	–	﹤0.01%	1542
2024 Q4	$63	Sell	3 -1	-25%	-$21	﹤0.01%	1549
2024 Q3	$80	Hold	4	–	–	﹤0.01%	1583
2024 Q2	$62	Hold	4	–	–	﹤0.01%	1608
2024 Q1	$64	Sell	4 -1	-20%	-$15	﹤0.01%	1599
2023 Q4	$85	Buy	5 +1	+25%	+$14	﹤0.01%	1564
2023 Q3	$47	Buy	4 +2	+100%	+$27	﹤0.01%	1591
2023 Q2	$27	Hold	2	–	–	﹤0.01%	1577
2023 Q1	$34	Buy	+2	New	+$33	﹤0.01%	1543

Other funds holding CPRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

SJS Investment Consulting's CPRX Position: Q2 2026 in Review

SJS Investment Consulting increased its Catalyst Pharmaceutical (CPRX) stake by 200% in Q2 2026, buying an estimated $118 and bringing the position to 6 shares worth $189. The position accounts for ﹤0.01% of the portfolio, ranked #2487.

SJS Investment Consulting first reported a position in CPRX in Q1 2023 and has held it in 14 quarters since. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

SJS Investment Consulting held 6 shares of Catalyst Pharmaceutical worth $189 as of Q2 2026.
SJS Investment Consulting bought 4 Catalyst Pharmaceutical shares in Q2 2026, an estimated $118.
Catalyst Pharmaceutical made up ﹤0.01% of SJS Investment Consulting's portfolio in Q2 2026, its #2487 holding.
SJS Investment Consulting first reported a position in Catalyst Pharmaceutical in Q1 2023 and has held it in 14 quarters since.
396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.